Literature DB >> 2407352

Interleukin-6 enhances the induction of human lymphokine-activated killer cells.

G Gallagher1, W H Stimson, J Findlay, F al-Azzawi.   

Abstract

Human peripheral blood mononuclear cells develop a powerful lytic capacity when cultured in vitro with interleukin-2 (IL-2), becoming lymphokine-activated killer cells (LAK cells). As part of an investigation into means of influencing this process, the effect of other cytokines has been examined. In this study we describe the ability of interleukin-6 (IL-6) to regulate the induction and function of human LAK cells. The results show that substitution of IL-6 for IL-2 did not lead to the development of functional LAK cells, nor was IL-6 able to alter the lytic capacity of established LAK cells. However, when IL-6 was included with IL-2 during the induction phase of the LAK cells, the resulting cells displayed considerably greater lytic activity than those prepared with IL-2 alone. This effect was IL-6 dose-related. These results indicate that LAK cell development may be positively regulated in vitro; the implications of this observation for the clinical usage of LAK cells are discussed.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2407352     DOI: 10.1007/bf01742495

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  15 in total

1.  Human antibodies to ovarian cancer antigens secreted by lymphoblastoid cell lines.

Authors:  F Al-Azzawi; W H Stimson; A D Govan
Journal:  J Clin Lab Immunol       Date:  1987-02

2.  Multiple actions of interleukin 6 within a cytokine network.

Authors:  G G Wong; S C Clark
Journal:  Immunol Today       Date:  1988-05

Review 3.  Cancer immunotherapy using interleukin-2 and interleukin-2-activated lymphocytes.

Authors:  S A Rosenberg; M T Lotze
Journal:  Annu Rev Immunol       Date:  1986       Impact factor: 28.527

4.  Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays.

Authors:  T Mosmann
Journal:  J Immunol Methods       Date:  1983-12-16       Impact factor: 2.303

5.  Human recombinant IL-4 suppresses the induction of human IL-2 induced lymphokine activated killer (LAK) activity.

Authors:  B Brooks; R C Rees
Journal:  Clin Exp Immunol       Date:  1988-11       Impact factor: 4.330

6.  Recombinant human B cell stimulatory factor 2 (BSF-2/IFN-beta 2) regulates beta-fibrinogen and albumin mRNA levels in Fao-9 cells.

Authors:  T Andus; T Geiger; T Hirano; H Northoff; U Ganter; J Bauer; T Kishimoto; P C Heinrich
Journal:  FEBS Lett       Date:  1987-08-31       Impact factor: 4.124

7.  Interleukin 6 enhancement of interleukin 3-dependent proliferation of multipotential hemopoietic progenitors.

Authors:  K Ikebuchi; G G Wong; S C Clark; J N Ihle; Y Hirai; M Ogawa
Journal:  Proc Natl Acad Sci U S A       Date:  1987-12       Impact factor: 11.205

8.  Separate but complementary roles for the two forms of interleukin 1 in the growth of transformed human B lymphoblasts.

Authors:  G Gallagher; N Taylor; J Willdridge
Journal:  Scand J Immunol       Date:  1987-09       Impact factor: 3.487

9.  Transforming growth factor-beta inhibits the in vitro generation of lymphokine-activated killer cells and cytotoxic T cells.

Authors:  J J Mulé; S L Schwarz; A B Roberts; M B Sporn; S A Rosenberg
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

10.  Induction of rat acute-phase proteins by interleukin 6 in vivo.

Authors:  T Geiger; T Andus; J Klapproth; T Hirano; T Kishimoto; P C Heinrich
Journal:  Eur J Immunol       Date:  1988-05       Impact factor: 5.532

View more
  14 in total

1.  Subpopulations of mononuclear leukocytes associated with inhibition of Ehrlich ascites tumor growth by treatment with Bothrops jararaca venom.

Authors:  Mariana Morena de Vieira Santos; Reinaldo José da Silva; Márcia Guimarães da Silva; Denise Fecchio
Journal:  Mediators Inflamm       Date:  2004-02       Impact factor: 4.711

2.  T-cell mediated anti-tumor immunity after photodynamic therapy: why does it not always work and how can we improve it?

Authors:  Florian Anzengruber; Pinar Avci; Lucas Freitas de Freitas; Michael R Hamblin
Journal:  Photochem Photobiol Sci       Date:  2015-06-11       Impact factor: 3.982

3.  Interleukin-6 does not support interleukin-2 induced generation of human lymphokine-activated killer cells.

Authors:  H G Klingemann; E Wong
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

4.  Suppression of lymphokine-activated killer (LAK) cell induction mediated by interleukin-4 and transforming growth factor-beta 1: effect of addition of exogenous tumour necrosis factor-alpha and interferon-gamma, and measurement of their endogenous production.

Authors:  B Brooks; K Chapman; J Lawry; A Meager; R C Rees
Journal:  Clin Exp Immunol       Date:  1990-12       Impact factor: 4.330

5.  Interleukin-6 directly influences proliferation and invasion potential of head and neck cancer cells.

Authors:  Takeharu Kanazawa; Hiroshi Nishino; Masahiro Hasegawa; Yasushi Ohta; Yukiko Iino; Keiichi Ichimura; Yutaka Noda
Journal:  Eur Arch Otorhinolaryngol       Date:  2007-02-20       Impact factor: 2.503

6.  Immune function of patients receiving recombinant human interleukin-6 (IL-6) in a phase I clinical study: induction of C-reactive protein and IgE and inhibition of natural killer and lymphokine-activated killer cell activity.

Authors:  C Scheid; R Young; R McDermott; L Fitzsimmons; J H Scarffe; P L Stern
Journal:  Cancer Immunol Immunother       Date:  1994-02       Impact factor: 6.968

7.  Induction of lymphokine-activated killer activity in mice by prothymosin alpha.

Authors:  C N Baxevanis; A D Gritzapis; G V Dedoussis; N G Papadopoulos; O Tsolas; M Papamichail
Journal:  Cancer Immunol Immunother       Date:  1994-04       Impact factor: 6.968

8.  Development of four donor-specific phenotypes in human long-term lymphokine-activated killer cell cultures.

Authors:  I Vollenweider; R Moser; P Groscurth
Journal:  Cancer Immunol Immunother       Date:  1994-11       Impact factor: 6.968

9.  Antitumor effects of recombinant interleukin-6 expressed in eukaryotic cells.

Authors:  A Eisenthal; H Kashtan; M Rabau; V Ramakrishna; S Chaitchik; Y Skornick
Journal:  Cancer Immunol Immunother       Date:  1993       Impact factor: 6.968

10.  Immunomodulation in patients receiving intravenous Bryostatin 1 in a phase I clinical study: comparison with effects of Bryostatin 1 on lymphocyte function in vitro.

Authors:  C Scheid; J Prendiville; G Jayson; D Crowther; B Fox; G R Pettit; P L Stern
Journal:  Cancer Immunol Immunother       Date:  1994-10       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.